Evidence map›Paper›PMID 39712158›Full record

ArticleActa crystallographica. Section E, Crystallographic communications2024

Crystal structures of two different multi-component crystals consisting of 1-(3,4-di-meth-oxy-benz-yl)-6,7-di-meth-oxy-iso-quinoline and fumaric acid.

Hiroki Shibata, Aya Sakon, Noriyuki Takata, Hiroshi Takiyama

Abstract read
In one paragraph

Article in Acta crystallographica. Section E, Crystallographic communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hiroki ShibataPharmaceutical Technology Division, Analytical Development Department, Chugai Pharmaceutical Co. Ltd., 5-5-1 Ukima, Kita-ku, Tokyo 115-8543, Japan.ORCID https://orcid.org/0009-0003-9377-7811
Aya SakonPharmaceutical Technology Division, Formulation Development Department, Chugai Pharmaceutical Co. Ltd., 216 Totsuka-cho, Totsuka-ku, Yokohama, Kanagawa 244-8602, Japan.ORCID https://orcid.org/0009-0001-0057-3429
Noriyuki TakataManufacturing Technology Division, Quality Development Department, Chugai Pharma Manufacturing Co. Ltd., 2500 Takayanagi, Fujieda, Shizuoka 426-0041, Japan.
Hiroshi TakiyamaDepartment of Applied Physics and Chemical Engineering Tokyo University of Agriculture and Technology 2-24-16 Naka-cho Koganei Tokyo 184-8588 Japan.ORCID https://orcid.org/0000-0002-4564-0808

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two different multi-component crystals consisting of papaverine [1-(3,4-di-meth-oxy-benz-yl)-6,7-di-meth-oxy-iso-quinoline, C

Indexed as

crystal structurefumaric acidmulti-component crystalpapaverine

Identifiers

PMID39712158
PMCPMC11660478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.